CCR2 and cancer: A potential limitation of STING agonists when used in combination with radiation is the radiation-associated recruitment of MDSCs that confer radiation resistance.87 MDSCs in the TME have been implicated in poor cancer patient prognosis, metastatic disease and immunotherapy resistance.52,104 Activation of type I IFN signaling might be one of the mechanisms recruiting these immunosuppressive cells within the TME.52,87 To limit MDSC recruitment a CCR2 antibody could be used since CCR2 is an MDSC attractant, and CCR2 inhibition has been shown to overcome immunosuppressive radiation effects.87